Key Highlights

  • Shares traded at $1.95 in today's intraday trading, up 0.52%, in penny-stock territory.
  • Second-quarter 2026 Revenue declined amid funding headwinds affecting Seer's academic and biopharma customers.
  • The company reaffirmed its 2026 revenue guidance of roughly $16 million to $18 million.
  • Seer's Proteograph platform uses nanoparticle technology to enable large-scale study of proteins.

Penny stock Seer (NASDAQ:SEER) is a life-sciences company that has developed a proteomics platform, its Proteograph product, which uses nanoparticle technology to enable large-scale study of proteins. Shares traded at $1.95 in today's intraday trading, up 0.52%.

Its customers are researchers and organizations in academia and biopharma, so its results depend on adoption of its Proteograph platform and consumables, its revenue growth, and its ability to fund operations, and it has faced funding headwinds affecting its academic and biopharma customers.

Latest Developments

In its second-quarter 2026 results, Seer reported a revenue decline amid funding headwinds affecting its academic and biopharma customers, while reaffirming its 2026 revenue guidance of roughly $16 million to $18 million and highlighting scientific validation and its AI-driven proteomics efforts. Investors should confirm the latest revenue and its trend, instrument and consumable sales, and the cash position directly from SEC filings.

Financial and Business Position

Seer's financial position is defined by its early-stage proteomics-platform revenue, its ongoing losses, and its substantial cash position, which provides a cushion. Investors should watch revenue and its trend, instrument and consumable sales, and the funding environment for academic and biopharma research.

Stock-Market Context

SEER shares traded at $1.95 in today's intraday trading, up 0.52%, keeping the stock in penny territory. The stock is a pre-profit life-sciences tools company whose shares are volatile and sensitive to revenue trends and the funding environment for research.

What Investors Should Watch

Watch revenue and its trend, instrument and consumable sales, gross margins, the net loss and cash burn, and the funding environment for academic and biopharma research. Renewed adoption of its Proteograph platform and revenue growth, aided by an improving research-funding environment, would be the most direct factors that could reverse the momentum.